Compare AUR & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AUR | PTGX |
|---|---|---|
| Founded | 2017 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.4B | 9.3B |
| IPO Year | 2021 | 2016 |
| Metric | AUR | PTGX |
|---|---|---|
| Price | $6.50 | $148.09 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 13 |
| Target Price | $9.43 | ★ $108.23 |
| AVG Volume (30 Days) | ★ 29.4M | 443.3K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 4.35 | N/A |
| EPS | N/A | ★ 2.35 |
| Revenue | ★ $3,000,000.00 | N/A |
| Revenue This Year | $407.30 | $874.25 |
| Revenue Next Year | $1,134.58 | N/A |
| P/E Ratio | ★ N/A | $61.74 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.60 | $57.90 |
| 52 Week High | $8.57 | $160.81 |
| Indicator | AUR | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 52.75 | 46.83 |
| Support Level | $5.53 | $141.95 |
| Resistance Level | $6.75 | $160.81 |
| Average True Range (ATR) | 0.31 | 5.60 |
| MACD | 0.07 | -1.45 |
| Stochastic Oscillator | 80.00 | 13.03 |
Aurora Innovation is a US autonomous driving provider for heavy trucks. The company produces and sells its Aurora Driver system, which includes hardware installed in a vehicle, software to autonomously drive it, and data management to maintain and improve the software. Aurora targets long-haul routes. The company currently offers its trucking-as-a-service model, where it owns and operates the trucks and makes deliveries for customers. The company plans to start selling its driver-as-a-service model next year, where fleet owners will own the trucks and Aurora's software will operate them.
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.